Market research
SLRX Salarius Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- Not available
- Beta
- 0.32
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US79400X4043
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- Not available
- Beta
- 0.32
About
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SLRX discussion.
5 years, 4 months ago
Salarius Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 24.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Salarius Pharmaceuticals, Inc's total revenue rose by 42.4% to $1M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-2K since the same quarter in the previous year.
Finally, its free cash flow grew by 47.8% to $-1M since the same quarter in the previous year.
Based on the above factors, Salarius Pharmaceuticals, Inc gets an overall score of 4/5.